Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer?

Article Tools ONCOLOGY GRAND ROUNDS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. January 08, 2019 ARTICLE CITATION DOI: 10.1200/JCO.18.01534 Journal of Clinical Oncology - published online before print January 24, 2019 PMID: 30676857 Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer? Aaron Lisberg, MD1xAaron LisbergSearch for articles by this author and Edward Brian Garon, MD1xEdward Brian GaronSearch for articles by this author Show More 1David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA https://doi.org/10.1200/JCO.18.01534 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology Companion Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater